by Lance Smith | Oct 11, 2019 | Study Scavenger Clinical Trial Recruitment Platform
Successful completion of Phase 2 monotherapy trial paves way for Phase 3 trials in China in early 2020 CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands & SHANGHAI–(BUSINESS WIRE)–Sixth paragraph, second sentence should read: “DED is more...
by Lance Smith | Oct 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in HER2CLIMB-02, a randomized phase 3 clinical trial evaluating investigational agent tucatinib versus placebo, in combination with...
by Lance Smith | Oct 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform
WOBURN, Mass.–(BUSINESS WIRE)–Frequency Therapeutics (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that...
by Lance Smith | Oct 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform
The U.S. Food and Drug Administration (FDA) has awarded $2 million to support a Phase 2 clinical trial testing whether daily supplementation of vitamin D reduces the risk of respiratory complications in children and adolescents with sickle cell disease (SCD). Gary M....
by Lance Smith | Oct 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform
NEW YORK, Oct. 10, 2019 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors...
by Lance Smith | Oct 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced enrollment of the first patient into the CHEETAH study, a prospective, multi-center U.S. study to evaluate the safety and performance of the Indigo System with CAT...